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Recent use of oral contraceptive pills is associated with a modest risk of breast cancer among very young women. In this US
population-based case–control study, we evaluated whether the excess risk associated with recent oral contraceptive use is
ubiquitous for all pill types or attributable to specific oral contraceptive preparations. Hormonal content and potency of combination
oral contraceptives used for the longest duration within 5 years of interview for breast cancer cases aged 20–44 years (N¼1640)
were compared with age-matched community controls (N¼1492). Women who recently used oral contraceptives containing more
than 35mg of ethinyl oestradiol per pill were at higher risk of breast cancer than users of lower dose preparations when compared to
never users (respective relative risks of 1.99 and 1.27, Ptrendo0.01). This relationship was more marked among women o35 years of
age, where risks associated with high- and low-dose ethinyl oestradiol use were 3.62 and 1.91 (Ptrendo0.01), respectively. We also
found significant trends of increasing breast cancer risk for pills with higher progestin and oestrogen potencies (Ptrendo0.05), which
were most pronounced among women aged o35 years of age (Ptrendo0.01). Risk was similar across recently used progestin types.
Our findings suggest that newer low-potency/low oestrogen dose oral contraceptives may impart a lower risk of breast cancer than
that associated with earlier high-potency/high-dose preparations.
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A small study of women with early-onset breast cancer published
in 1983 initially sparked the debate about combination oral
contraceptives and breast cancer by suggesting that a woman’s risk
of breast cancer increased if she used oral contraceptives early in
life, particularly pills with high progestin potency (Pike et al,
1983). Evidence from a multitude of case–control and cohort
studies conducted in the 1980s and early 1990s subsequently found
a modest (approximately 20–40%) but consistent excess in breast
cancer risk associated with recent oral contraceptive use among
women younger than 45 years of age (Collaborative Group on
Hormonal Factors in Breast Cancer, 1996a). Whether this excess
risk is ubiquitous for all pill types or attributable to specific oral
contraceptive preparations is considerably less well studied.
The majority of investigations that report risk associated with
specific oral contraceptive preparations among women younger
than 45 years of age assess lifetime exposure to oral contraceptives
instead of the more relevant exposure, recent use (Pike et al, 1983;
Vessey et al, 1983, 1989; McPherson et al, 1987; Jick et al, 1989; UK
National Case–Control Study Group, 1989; White et al, 1994;
Brinton et al, 1995; Ursin et al, 1998). Consequently, there have
been mixed reports of increased breast cancer risk associated with
high progestin potency pills (White et al, 1994; Pike et al, 1983),
and oestrogen content, specifically ethinyl oestradiol use (McPher-
son et al, 1987; Jick et al, 1989) and long-term use of high-dose
oestrogen pills (X50mg) (UK National Case–Control Study
Group, 1989; Ursin et al, 1998). Three of the nine studies
examining hormonal content of combination oral contraceptives
among women younger than 45 years reported no association with
either oestrogen or progestin content (Vessey et al, 1983, 1989;
Brinton et al, 1995), but two of three employed unadjusted
estimates of risk associated with ever use and the third, an early
analysis of the data presented in this paper, focused on duration of
use. Although a collaborative reanalysis assessing 26 studies with
data on hormonal content of combined oral contraceptive
preparations (which included data from this study) observed no
association of first used, longest used, or most recently used oral
contraceptive formulation with breast cancer risk, these results
were based on a large proportion of older women for whom oral
contraceptive use is not a breast cancer risk factor (Marchbanks
et al, 2002): 66% of data analysed were from women 45 years of age
or older and subgroup analyses among younger women were
limited (Collaborative Group on Hormonal Factors in Breast
Cancer, 1996b).
Since Food and Drug Administration (FDA) approval in 1960,
the oral contraceptive pill has been formulated using two
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yoestrogens and nine different progestins, varying in both dose and
potency (Piper and Kennedy, 1987). Oral contraceptives under-
went considerable changes in formulation during the 1970s and
1980s, so that by the 1990s they contained approximately one-
fourth the oestrogen and one-tenth the progestin of earlier
versions (Boonstra et al, 2000). Thus, it is plausible that risk
associated with oral contraceptive use may be altered over time
because of changes in formulation. In fact, recent investigations of
the association of oral contraceptives with ovarian cancer, one of
which was from a large population-based study (Schildkraut et al,
2002), suggest that formulations with higher progestin (Schild-
kraut et al, 2002) or oestrogen potency (Rosenberg et al, 1994;
Rosenblatt et al, 1992) conferred a greater reduction in risk of
ovarian cancer than those with lower potency. In this study, we
investigate whether differences exist in breast cancer risk
associated with recent oral contraceptive use for newer low-
potency pills and older higher-dose preparations. This paper
reports a comprehensive analysis of the relationship of oral
contraceptive formulation with breast cancer risk by examining
oestrogen and progestin type, dose, and potency using data from a
large population-based case–control study specifically designed to
answer this question.
MATERIALS AND METHODS
Subjects
Brinton et al (1995) previously described this population-based
case–control study. Briefly, the breast cancer case subjects in this
investigation included patients, 20–54 years of age, newly
diagnosed with in situ or invasive breast cancer in 1990–1992
while living in either the metropolitan areas of Atlanta, Georgia or
Seattle/Puget Sound, Washington, or five counties of central New
Jersey. Regional and governmental institutional review boards
approved the study protocol. Hospital records of eligible patients
were abstracted to document details on the clinical and pathologic
characteristics of the breast cancers. Control subjects in the three
geographic areas were ascertained through random-digit dialling,
with a 90.5% screening response rate.
Data collection
Following written informed consent, participants were interviewed
in person about oral contraceptive pill use from menarche until the
date of interview. Pregnancies and other life events were first
marked on a month-by-month family planning calendar to serve as
a frame of reference and to aid recalling dates of changes in
contraceptive use over time. Months of oral contraceptive use were
subsequently shaded on the calendar. On a complementary
worksheet, interviewers recorded the start and stop dates for each
episode of pill usage, the brand name, reason for use, and reason
for discontinuing use. Colour photographs of oral contraceptives
and listings of the year they were first marketed in the United
States were shown to help participants identify the brand name of
each oral contraceptive used.
In addition, in-person interviews included questions about
demographic factors, reproductive and menstrual history, use of
exogenous hormones, medical and screening history, anthropo-
metry and physical activity, adolescent diet, alcohol consumption,
smoking, occupation, family history of cancer, and certain lifestyle
factors. Interviews were obtained from 2002 eligible patients (86%)
and 2009 eligible control subjects (78%). A comparison of
respondents to nonrespondents who were willing to complete an
abbreviated questionnaire reported no important differences for
the distributions of variables assessed in this study (Madigan et al,
2000).
Exclusions
This investigation included only women younger than 45 years of
age (N¼3132), the age group for which oral contraceptive use is a
risk factor for breast cancer (Collaborative Group on Hormonal
Factors in Breast Cancer, 1996a). We excluded from analysis
patients who indicated on interview that they either did not have a
residential telephone (n¼28) or that they had a previous diagnosis
of breast cancer (n¼19). We also excluded 16 of the young women
who used solely progestin-only pills. After the exclusions, 1640
cases and 1429 controls remained in this investigation.
Defining oral contraceptive formulation and potency
Oral contraceptive use was defined as use of combination oral
contraceptive pills for a total of 6 or more months. Women who
never used oral contraceptives or who used them for less than 6
months were classified as nonusers. For each oral contraceptive
preparation used, we obtained information on oestrogen and
progestin content and dose from the Physician’s Desk Reference
available during the time that the preparation was marketed in the
United States (Table 1). Oral contraceptive preparations were
grouped according to oestrogen content and dose (p50mg, 51–
99mg, or 100+mg mestranol; p35mg or 36+ mg ethinyl oestradiol)
and progestin content (dimethisterone, chlormadinone acetate,
norethynodrel, ethinyl diacetate, norethindrone, norethindrone
acetate, norgestrel, and levonorgestrel).
In addition to assessing breast cancer risk associated with
oestrogen and progestin types, we also evaluated oestrogen and
progestin potencies for each pill preparation. To this end, we
classified combined oral contraceptive pills into hormone potency
categories using a method described in a standard pharmacy
reference text (Drug Facts and Comparisons, 1997), which has been
used previously by the FDA (Piper and Kennedy, 1987). Oestrogen
potency data were based on mouse uterine weight gain and human
uterine volume analysis and progestin potency on delay of menses
data in humans and the degree of glycogen incorporation in
human endometrial vacuoles. The categorisation scheme simulta-
neously ranks oestrogen and progestin potencies as low, inter-
mediate, or high for each product. For this analysis, we condensed
this classification scheme to create a categorical variable with four
levels describing hormone potency: high progestin/high oestrogen,
high progestin/low oestrogen, low progestin/high oestrogen, or low
progestin/low oestrogen potency. High- and low-potency prepara-
tions as described in the standard pharmacy text were classified as
high and low, respectively, for this analysis. We divided the
preparations that fell in the intermediate oestrogen potency
category (in the pharmacy text) into high- and low-potency
groups for this analysis. Oral contraceptive formulations with
35mg ethinyl oestradiol or 50mg mestranol were classified as high
potency since these doses are approximately biologically equiva-
lent (Brody et al, 1989). Those with less than 35mg ethinyl
oestradiol or 50mg mestranol were classified as low potency.
Intermediate progestin potency from the classification scheme was
assigned to the low progestin potency group for this analysis.
Products not included in the textbook potency classification
scheme were evaluated for hormonal content and dose, and
assigned to a potency group by the authors (listed in italics in
Table 1).
Since oral contraceptive users reported multiple episodes of
usage, determining how to assess a series of pill preparations was
complex. A reanalysis of data from 54 epidemiologic studies and
over 100000 women found that of all the ways to look at oral
contraceptive use, recency was both independent and the strongest
predictor of breast cancer risk (Collaborative Group on Hormonal
Factors in Breast Cancer, 1996a). In that study, risk was attenuated
after discontinuation of oral contraceptives and, 10 years after
discontinuation of pills, risk was similar to never-users. Further-
Oral contraceptive formulation and breast cancer
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British Journal of Cancer (2003) 88(1), 50–57 & 2003 Cancer Research UKTable 1 Combination oral contraceptive use among premenopausal WISH participants, by brand name and crossclassified by pill content and potency
Low progestin/high
oestrogen potency
Low progestin/low
oestrogen potency
High progestin/low
oestrogen potency
Low progestin/high
oestrogen potency
Progestin Mestranol Ethinyl oestradiol Ethinyl oestradiol Mestranol Mestranol Ethinyl oestradiol
Chlormadinone acetate
Dimethisterone
Ethynodiol diacetate Demulen 1/35
a (1/35) Ovulen
a (1/100) Demulen 1/35
a (1/35) Ovulen
a (1/100)
Demulen 1/50
a (1/50) Demulen 1/50
a (1/50)
Medroxyprogesterone acetate Provest
a (10/50) Provest
a (10/50)
Norethynodrel Enovid 10mg
a (9.85/150) Enovid 10mg
a (9.85/150)
Norethindrone Genora 1/50
a (1/50) Brevicon (0.5/35) Ortho-Novum 10mg
a Ortho-Novum 10mg
a
Norinyl 1/50 (1/50) Modicon (0.5/35) (10/60) (10/60)
Ortho-Novum 1/50 Nelova 1/35e
a (1/35) Norinyl 10mg
a (10/60) Norinyl 10mg
a (10/60)
(1/50) Norinyl 1/35 (1/35)
Tri-norinyl (0.5:1:0.5/35)
ORF 1557-BE
a (0.5/35)
ORF 1557-BF
a (1/35)
Ortho-novum 1/35 (1/35)
Ortho-novum 10/11 (0.5:1/35)
Ortho-novum 7/7/7 (0.5:0.75:1/35)
Ovcon 35 (0.4/35)
Norethindrone acetate Loestrin 1.5/30 (1.5/30) Norlestrin 1/50
a (1/50) Ovral (0.5/50)
Loestrin 1/20 (1/20) Norlestrin 2.5/50
a (2.5/50)
Norlestrin var red
a (1/20) Norlestrin low
a (0.5/50)
Zorane 1.5/30
a (1.5/30) Norlestrin var black
a
Zorane 1/20
a (1/20) (2/40)
Norgestrel Lo/Ovral (0.3/30) Ovral (0.5/50)
Ovral blue
a (0.15/30)
Ovral brown
a (0.15/15)
Levonorgestrel Levlen (0.15/35)
Nordette (0.15/30)
Tri-levlen (0.05:0.075:0.125/30:40:30)
Triphasil (0.05:0.075:0.125/30:40:30)
aOral contraceptives no longer marketed in the United States (not listed in the 2002 Physician’s Desk Reference).
Note: Progestin (mg) and oestrogen dose (mg) is indicated after each oral contraceptive brand name in parentheses. Italicized brand names were added to the potency scheme based on progestin and oestrogen content as evaluated by
the authors.
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Kmore, the relationship between recency and breast cancer risk was
not materially affected after adjusting for duration of use or use
prior to childbearing or prior to 25 years of age. This has also been
shown in a previous publication of the data from the present
investigation (Brinton et al, 1995). Thus, in this study, we have
assessed content of the oral contraceptive preparations used for
the longest duration in the period (1) within 5 years prior to
diagnosis and (2) within 10 years prior to diagnosis.
Statistical methods
We describe the use of combination oral contraceptives among
control subjects. Frequency distributions are used to summarise
categorical variables and means, standard deviations, and medians
for continuous variables.
The relationship between combination oral contraceptive use
(ever use and recency of use) and breast cancer risk is reported
overall and for two age strata: o35 and 35–44 years of age. Risk
associated with hormonal content and potency was also assessed
within these age strata after restricting the population to nonusers
and those who used oral contraceptives (1) within 5 and (2) within
10 years of diagnosis (cases)/interview (controls). We also
evaluated whether risk estimates for recently used pill formula-
tions varied by duration of oral contraceptive use by repeating the
above-described analyses separately for women who used pills for
less than 5 years or for 5 or more years in total.
Relative risks (RRs) and their 95% confidence intervals (CIs)
were used to assess whether breast cancer risk was elevated by oral
contraceptive use (ever vs never; recency of use) or by specific
hormonal preparations, stratifying by age group and controlling
for potential confounders. We used unadjusted and adjusted
logistic regression models to obtain maximum likelihood estimates
of the odds ratio, which were used to approximate RR (Breslow
and Day, 1980). To test whether the relationship between ever oral
contraceptive use and breast cancer diagnosis was modified by age
at diagnosis/interview on a multiplicative scale, both the main
effects and their interaction term were evaluated in the model and
the statistical significance of the interaction term was assessed. All
final models adjusted for study site (Atlanta, Seattle, New Jersey),
age (continuous), race (white, black, others), number of mammo-
grams within 5 years of interview (continuous), menopausal status
(pre-, postmenopausal), age at menarche (o12, 12, 13, 14+ years),
a combination variable including number of full-term births and
age at first birth (no birth, 1 birth at age o25 years, 1 birth at age
X25 years, 2 births at age o25 years, etc), family history of breast
cancer in a first-degree relative (yes or no), and body mass index
(kgm
 2, continuous). All tests were two-sided, and P values less
than 0.05 were considered to be statistically significant.
RESULTS
Use of combination oral contraceptive use among control
subjects
A total of 73% of 1429 control subjects in these analyses used
combination oral contraceptives for a minimum of 6 months prior
to interview. Although the proportion of ever-users increased with
age (67, 72, and 74% for women aged o35, 35–39, and 40–44
years, respectively), younger women were more likely to have used
combination oral contraceptives within 5 years prior to interview
(43, 21, 6% for the youngest to oldest age groups).
As shown in Table 2, half of control women reported ever using
low progestin/low oestrogen potency preparations (50%); however,
approximately a third of women took high oestrogen potency
(37%, including combination pills with either high or low
progestin potency) or high progestin potency pills (30%, including
combination pills with either high or low oestrogen potency). Only
12% of women ever used combination oral contraceptives that
were of both high progestin and oestrogen potencies. Similar
proportions of women took mestranol (55%) and ethinyl
oestradiol-containing pills (56%), whereas ever use of preparations
containing the progestin norethindrone was reported by the
majority of women (61%).
The use of combination oral contraceptive formulations by
control subjects in this population paralleled the introduction of
new preparations into the US market (Table 2). Women who used
either high-potency or high oestrogen dose formulations began pill
use earlier in calendar time and were older at interview than those
who used lower-potency/dose preparations. For example, the
median year at first use of high progestin/high oestrogen potency
pills was 1969 with a mean age at diagnosis/interview of 40.6 years,
as opposed to first use in 1973 with an average age at diagnosis/
interview of 36.7 years for low progestin/low oestrogen formula-
tions. Women who used high-dose or high-potency formulations
tended to be slightly younger at the time of first use and used these
preparations for a shorter duration, as compared to women taking
low-dose or low-potency formulations.
Hormonal content and potency of combination oral
contraceptives and breast cancer risk
Risk of breast cancer associated with combination oral contra-
ceptive use diminished with increasing age (from o35 to 35–44
years) and with time since last use (Table 3). Since the relationship
between oral contraceptive use and breast cancer risk depended on
the woman’s age at diagnosis (Pinteractiono0.05), subsequent
analyses are presented within age strata defined by o35 and
35–44 years.
Women younger than 35 years of age who used oral contra-
ceptives within 5 years of interview were at the highest risk of
breast cancer with a RR of 2.22. Risk was elevated, although not
significantly, among recent oral contraceptive users aged 35–44
years (RR¼1.30). Since risk was most elevated among recent oral
contraceptive users in this and other populations (Collaborative
Group on Hormonal Factors in Breast Cancer, 1996a), we focused
our assessment of the effects of dose and potency on pill
preparations used for the longest duration in the 5 years prior to
interview. Some residual risk existed among women who last used
pills 6–10 years prior to interview, particularly among women
younger than 35 years; therefore, we also assessed pill preparations
used during the 10 years prior to interview and found trends
slightly diluted, particularly in the older age group. For brevity, we
only present findings among the most recent users (Table 4).
Among combination oral contraceptive users in this study,
younger women were more likely to recall pill brand names: 93%
of women younger than 35 years and 81% of those aged 35–44
provided at least one brand of pill that they used. Since breast
cancer risk was slightly higher among women who could not recall
pill brand names (as shown in Table 3), we included a category for
unknown formulation in the final models (Table 4).
Hormonal content and potency of the pill preparation used for
the longest duration in the 5 years prior to interview and breast
cancer risk is summarised in Table 4. When compared to
nonusers, a higher dose of ethinyl oestradiol pills was significantly
associated with higher breast cancer risk, overall (Ptrendo0.01) and
within each age group (Ptrendo0.01 for women aged 20–34 years
and 0.13 for those aged 35–44 years). Women aged 20–44 years
who used pills containing more than 35mg of ethinyl oestradiol
were at an approximately 50% higher risk of breast cancer than
recent users of lower-dose preparations when compared to
nonusers (respective RRs of 1.99 and 1.27). This relationship was
most pronounced in the youngest age group, where risk associated
with high- and low-dose ethinyl oestradiol use was 3.62 and 1.91,
respectively. Breast cancer risk associated with mestranol was
almost entirely explained by doses higher than 50mg per pill
Oral contraceptive formulation and breast cancer
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British Journal of Cancer (2003) 88(1), 50–57 & 2003 Cancer Research UKamong women younger than 35 years; however, risk was slightly
lower among high- compared to low-dose mestranol users in the
older age group. With the exception of ethynodiol diacetate
(RR¼12.0 among women aged 20–34 years based on 12 cases and
three controls), risk was similar across all progestin types recently
used by women in this study.
In addition to hormonal content, we also examined the
relationship between oestrogen and progestin potency and breast
cancer risk (Table 4). High progestin potency pills were most
strongly related to breast cancer risk among women younger than
35 years of age, with a RR of 8.11 (2.1–31.6). Within this age
group, risk was also elevated for recent users of low progestin
potency pills (RR¼1.83; 95% CI, 1.1–3.0). In the youngest age
group, risk of breast cancer increased with higher oestrogen
potency pill preparations (Ptrendo0.01). Combination progestin/
oestrogen potency similarly showed a significant trend of
increasing breast cancer risk with increasing potency
(Ptrendo0.01); recent use of low progestin/low oestrogen potency
pills was associated with a RR of 1.79, low progestin/high
oestrogen potency with a RR of 2.53, and high progestin/low
oestrogen potency with a RR of 8.07. No woman aged younger
than 35 years recently used high progestin/high oestrogen potency
pills. High progestin/high oestrogen potency pills were used only
by women aged 35–44 years (n¼7), with a RR of 1.54, only
slightly higher than the risk associated with low progestin/low
oestrogen pills (RR¼1.27) in this age group. Similar trends were
seen with hormonal potency among women aged 20–44 years
(Ptrendo0.05), although not as strong as in the youngest age group.
The association of breast cancer risk with hormonal content and
potency of oral contraceptive preparations was similar to the
findings presented in Table 4 for women who used pills for less
than 5 years and for those who used them for 5 or more years and
after adjusting for frequency of self-breast examination.
DISCUSSION
In this population-based study of women younger than 45 years of
age, we found that breast cancer risk increased with either higher
oestrogen dose or higher progestin or oestrogen potency pills used
within 5 years of interview, and that these findings were more
marked among women younger than 35 years of age. Our findings
and those from other studies have shown that recent oral
contraceptive use imparts a modest excess in breast cancer risk
among women younger than 45 years of age and that this
relationship is strongest among very young women (Wingo et al,
1993; Collaborative Group on Hormonal Factors in Breast Cancer,
1996a). Previous investigations of oral contraceptive preparations
did not integrate these elements (e.g. recency of use and young age
at diagnosis) into their study design, but rather included women
older than 45 years and assessed lifetime exposure, first used, most
used, or last used oral contraceptive preparation, rendering their
findings difficult to untangle (Pike et al, 1983; Vessey et al, 1983,
1989; Jick et al, 1989; UK National Case–Control Study Group,
1989; White et al, 1994; Collaborative Group on Hormonal Factors
in Breast Cancer, 1996b; Ursin et al, 1998; McPherson et al, 1987).
Nonetheless, the majority of these studies found weak trends,
suggesting a higher risk with increasing oestrogen dose, or
estrogen/progestin potency among women younger than 45 years
of age (Pike et al, 1983; McPherson et al, 1987; Jick et al, 1989; UK
National Case–Control Study Group, 1989; White et al, 1994;
Collaborative Group on Hormonal Factors in Breast Cancer, 1996b;
Ursin et al, 1998).
Progestins contained in oral contraceptives differ in both dose
and potency (Collins, 1994). For example, norethindrone, nor-
ethindrone acetate and ethynodiol diacetate are roughly equivalent
in potency, while norgestrel is roughly 5–10 times and
levonorgestrel is 10–20 times more potent (Dorflinger, 1985).
Table 2 Use of combination oral contraceptive (OC) preparations among control subjects
Oestrogen/progestin content Controls Year of first OC use Age at interview (y) Age at first OC use (y)
Months of use
Any OC Specified OC
Any OC use 1086 (100%) 1972 38.5 (4.46) 19.9 (3.21) 68.1 (52.6)
Potency
High progestin/high oestrogen 130 (12%) 1969 40.6 (2.88) 19.1 (2.54) 72.9 (51.4) 58.5 (41.0)
Low progestin/high oestrogen 270 (25%) 1970 39.7 (3.67) 19.4 (2.65) 74.0 (55.1) 59.3 (45.1)
High progestin/low oestrogen 193 (18%) 1972 39.0 (3.46) 19.8 (3.08) 80.0 (53.5) 62.1 (43.3)
Low progestin/low oestrogen 546 (50%) 1973 36.7 (4.81) 20.0 (3.45) 79.9 (56.8) 67.9 (49.7)
Oestrogen content and dose
Mestranol
>100mg 212 (20%) 1969 40.6 (3.04) 19.0 (2.60) 72.0 (52.8) 57.6 (42.8)
51–99mg 141 (13%) 1971 39.1 (3.78) 19.6 (2.79) 75.9 (56.2) 58.3 (40.5)
p50mg 242 (22%) 1973 37.7 (4.05) 19.9 (3.23) 77.2 (52.6) 63.7 (45.2)
Ethinyl oestradiol
>35mg 247 (23%) 1972 38.4 (4.29) 20.0 (3.26) 80.1 (55.0) 62.6 (43.9)
p35mg 354 (33%) 1974 35.9 (5.03) 19.8 (3.45) 84.2 (59.2) 67.0 (48.5)
Progestin content
Dimethisterone 3 (o1%) 1966 42.3 (1.15) 18.0 (1.73) 75.3 (73.1) 70.2 (78.7)
Chlormadinone acetate 17 (2%) 1966 42.5 (1.62) 19.2 (1.55) 66.9 (65.4) 41.5 (41.5)
Norethynodrel 29 (3%) 1969 40.6 (3.76) 19.0 (3.16) 64.1 (51.6) 45.3 (42.2)
Ethinyl diacetate 180 (17%) 1971 39.6 (3.44) 19.3 (2.83) 73.0 (52.1) 63.9 (48.1)
Norethindrone 663 (61%) 1972 38.0 (4.65) 19.8 (3.23) 72.5 (54.4) 66.1 (50.9)
Norethindrone acetate 70 (6%) 1972 38.2 (3.81) 20.0 (3.24) 81.2 (55.3) 70.7 (48.6)
Norgestrel 247 (23%) 1972 37.6 (4.38) 19.5 (2.93) 83.4 (55.1) 65.4 (46.4)
Levonorgestrel 54 (5%) 1978 33.4 (5.26) 20.8 (4.21) 75.4 (48.6) 55.7 (36.8)
Note: With the exception of median year of first oral contraceptive use, this table presents unadjusted means (s.d.) for control subjects who used oral contraceptives for a
minimum of 6 months. Oestrogen/progestin categories are not mutually exclusive. For example, a woman who used both mestranol and ethinyl oestradiol preparations is
counted in both categories.
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ceptives are essentially equipotent (Collins, 1994), perhaps
explaining the fairly uniform elevation in breast cancer risk across
progestin types seen in this study. Since the methods used to
determine hormonal potency simultaneously assess the action of
both the oestrogen and progestin components, our finding that
risk was associated with higher progestin potency, but not specific
progestin types, is not contradictory. It is also noteworthy that
assigning hormonal potency to different pill formulations is at best
an inexact science: potency estimates are derived from a
combination of different laboratory methods, none of which are
performed regularly in clinical practice (Drug Facts and Compar-
isons, 1997).
In addition to progestational activity, many progestins demon-
strate varying degrees of androgenic metabolic effects, being
derived from 19 nortestosterone (Mishell, 1989). Levonorgestrel is
the most androgenic progestin used in oral contraceptives today
followed by norgestrel (Phillips et al, 1987); the remaining
progestins are essentially devoid of androgen activity (Stubblefield,
1986). Nonetheless, we found no evidence of a trend with
increasing androgen activity of pill formulations. Although there
was some suggestion that levonorgestrel preparations imparted
one of the highest risks (RR¼1.77) among women aged 35–44
years, this finding was not evident among younger study
participants.
One of the weaknesses of this study was that pill brand name
was based on subject recall. Validation studies have shown that
recall of oral contraceptive use and timeframe of use is accurate,
but that recall of specific brand names is less accurate (Coulter
et al, 1986; Harlow and Linet, 1989). By employing structured, in-
person interviews using a combination of family planning
calendars to aid recall and comprehensive picture books of oral
contraceptive preparations, a fairly high percentage of oral
contraceptive users (83%) provided information on pill brand
names, and 93% of those younger than 35 years. Since slightly
more cases (18%) as compared to controls (15%) using oral
contraceptives provided information on pill brand names, and risk
of breast cancer among those with unknown formulations was also
slightly higher, we adjusted for subjects with unknown formula-
tions in our analysis.
Since their inception, oral contraceptive pills have undergone
substantial changes in formulation. For example, the FDA reported
that in 1964, 94% of the oral contraceptives dispensed by retail
pharmacies were high oestrogen potency pills, and by 1984, 85% of
oral contraceptives dispensed were low oestrogen potency pills
(Piper and Kennedy, 1987); the oestrogen in the older formulations
contained mestranol, while all those developed since 1974 contain
ethinyl oestradiol (Mishell, 1989; Wilson et al, 1998). Analysis of
the use of combination oral contraceptives among control subjects
parallel the introduction of new pill formulations into the US
market, suggesting that the quality of the pill brand names recalled
may be quite accurate. Among control subjects who used oral
contraceptives, the median year of first use of oral contraceptives
for women who used high oestrogen potency, high dose, or
mestranol-containing pills was earlier than for users of low
potency, low dose, or ethinyl oestradiol pills. Similarly, progestins
removed from the market prior to 1980, including chlormadinone
acetate, dimethisterone, and medroxyprogesterone acetate, and
norethynodrel, which was no longer marketed as of 1988, were
used by women who first took the pill earlier in calendar time than
those using norgestrel and levonorgestrel-containing pills that are
available in current formulations (Piper and Kennedy, 1987).
Although it is possible that the modest increase in breast cancer
risk associated with recent use of higher oestrogen dose or high-
potency pills is explainable by a detection bias, several plausible
biologic mechanisms exist. The steroid hormones of oral contra-
ceptives, oestrogen and 19-nortestosterone-derived progestogens,
have long been shown to stimulate breast cell mitotic activity by
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British Journal of Cancer (2003) 88(1), 50–57 & 2003 Cancer Research UKacting directly, alone or synergistically, on breast cells in vivo (Jeng
et al, 1992; Isaksson et al, 2001). The collaborative reanalysis
examined the use of screening mammography among controls and
found no evidence that recent users of oral contraceptives were
more likely to report having had a mammogram than never-users
(Collaborative Group on Hormonal Factors in Breast Cancer,
1996b). In addition, our findings do not appear to be susceptible to
a surveillance bias, as the estimates were similar after adjustment
for number of mammograms and for frequency of self-breast
examinations in the 5 years prior to diagnosis.
Although our findings suggest that newer low oestrogen dose/
low-potency oral contraceptives may impart a lower risk of breast
cancer than that associated with earlier high-dose/high-potency
preparations, we only had small numbers of women within strata
of specific pill preparations. Thus, reanalysis of earlier studies
(Pike et al, 1983; Vessey et al, 1983, 1989; McPherson et al, 1987;
Jick et al, 1989; UK National Case–Control Study Group, 1989;
White et al, 1994; Collaborative Group on Hormonal Factors in
Breast Cancer, 1996b; Ursin et al, 1998;) or analysis of formulation
data from earlier studies that has not yet been published (Meirik
et al, 1986; Paul et al, 1990; Weinstein et al, 1991; Wingo et al,
1993; Primic-Zakelj et al, 1995) would help to confirm our
findings.
Our analysis examines formulations of oral contraceptive pills
used prior to 1993. Since that time new major developments in pill
preparations include widespread use of third-generation proges-
tins with low androgenic activity, and further reduction in the
dosage of ethinyl oestradiol from 35 to 20mg per pill (Burkman,
2001). Since oral contraceptives are used by 80% of women at one
point during their reproductive lives, and women are now using
the pill for longer than ever before (Piccinino and Mosher, 1998),
even modest increases in risks associated with use can have a large
public health impact. New studies are necessary to assess whether
there is risk associated with newer oral contraceptive pill
formulations, including progestin-only preparations, which have
claimed an increasing market in recent times.
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Table 4 Breast cancer risk associated with hormonal potency and content of combination oral contraceptives used for the longest duration within 5 years
of interview
o35 years 35–44 years Total (o45 years)
Cases
(N=193)
Controls
(N=219) RR 95% CI
Cases
(N=487)
Controls
(N=445) RR 95% CI
Cases
(N=680)
Controls
(N=664) RR 95% CI
Nonusers 58 96 1.00 313 310 1.00 371 406 1.00
Oestrogen dose
Ethinyl estradiol
p35mg 81 80 1.91 1.1–3.2 80 67 1.02 0.7–1.5 161 147 1.27 0.9–1.7
>35mg 27 17 3.62 1.7–7.9 32 21 1.52 0.8–2.8 59 38 1.99 1.2–3.2
Mestranol
p50mg 14 17 1.17 0.5–2.8 29 21 1.52 0.8–2.9 43 38 1.38 0.8–2.3
>50mg 5 4 2.40 0.5–11.8 12 10 1.25 0.5–3.1 17 14 1.52 0.7–3.3
Unknown 8 5 1.93 0.5–6.8 21 16 1.31 0.6–2.7 29 21 1.52 0.8–2.8
Progestin content
Ethynodiol diacetate 12 3 12.0 2.4–59.2 8 10 0.82 0.3–2.2 20 13 1.94 0.9–4.2
Norethindrone 67 73 1.64 1.0–2.8 86 65 1.32 0.9–2.0 153 138 1.35 1.0–1.8
Norethindrone acetate 8 5 3.11 0.9–10.6 17 10 1.77 0.7–4.3 25 15 1.90 0.9–3.8
Norgestrel 21 17 1.97 0.9–4.5 25 23 0.71 0.4–1.3 46 40 1.14 0.7–1.9
Levonorgestrel 20 21 2.12 1.0–4.7 20 12 1.77 0.8–4.0 40 33 1.66 1.0–2.9
Unknown 7 4 2.36 0.6–9.4 18 15 1.30 0.6–2.8 25 19 1.59 0.8–3.1
Progestin potency
Low 114 115 1.83 1.1–3.0 140 103 1.28 0.9–1.8 254 218 1.40 1.1–1.8
High 14 4 8.11 2.1–31.6 16 17 0.84 0.4–1.8 30 21 1.54 0.8–2.8
Unknown 7 4 2.35 0.6–9.3 18 15 1.30 0.6–2.8 25 19 1.59 0.8–3.0
Oestrogen potency
Low 120 113 1.97 1.2–3.2 138 107 1.18 0.8–1.7 258 220 1.38 1.1–1.8
High 8 6 2.56 0.7–8.9 18 13 1.50 0.7–3.2 26 19 1.70 0.9–3.3
Unknown 7 4 2.32 0.6–9.2 18 15 1.30 0.6–2.8 25 19 1.58 0.8–3.0
Progestin/oestrogen potency
Low/low 106 109 1.79 1.1–2.9 126 93 1.27 0.9–1.8 232 202 1.37 1.0–1.8
Low/high 8 6 2.53 0.7–8.8 14 10 1.50 0.6–3.6 22 16 1.71 0.8–3.4
High/low 14 4 8.07 2.1–31.4 12 14 0.71 0.3–1.6 26 18 1.52 0.8–2.9
High/high 0 0 4 3 1.54 0.3–7.3 4 3 1.67 0.4–7.9
Unknown 7 4 2.34 0.6–9.3 18 15 1.31 0.6–2.8 25 19 1.58 0.8–3.0
Note: This table compares nonusers to women who used oral contraceptives within 5 years of interview. Subjects who used oral contraceptives, but not within 5 years of
interview, were excluded from analysis (N=1788). RRs and 95% CIs were estimated using maximum likelihood methods and adjusting for age, site, race, menopausal status, a
combination variable for age at first birth and number of births, age at menarche, family history of breast cancer, body mass index, and mammography use.
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